Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
about
Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development.Pertussis: Microbiology, Disease, Treatment, and Prevention.Fighting pertussis re-emergence: promise from vaccination in pregnancy.The Divergent CD8+ T Cell Adjuvant Properties of LT-IIb and LT-IIc, Two Type II Heat-Labile Enterotoxins, Are Conferred by Their Ganglioside-Binding B Subunits.Intramammary Immunization of Pregnant Mice with Staphylococcal Protein A Reduces the Post-Challenge Mammary Gland Bacterial Load but Not Pathology.Strategies and new developments to control pertussis, an actual health problemMucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant.Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection.Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.Outer membrane vesicles: an attractive candidate for pertussis vaccines.Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.
P2860
Q30245164-741DE6E6-2DF3-4309-AE9C-E9BEB6AA8010Q30251684-6F4D13E9-BC30-4DB4-A211-2B137CA08FEBQ35383525-E02C1B8D-83DE-4A21-9103-5C251167711DQ35840727-260203DC-332F-4C80-BC03-0A7459B08B8FQ35919380-2534F3D5-ABF0-4256-B1F3-BFB3B175E264Q36226470-7FEEA9D2-D5AC-4EFD-83C8-E746A9CD1AA0Q36372507-17B93268-139D-4850-94FD-5F2EE7AB7DC5Q37001755-FAB5338E-C4F2-49BF-A150-6E5D15FD1DDFQ39065890-8FAEF197-E67C-4AF1-B457-01983A4252F5Q40115767-D38A38A3-CFA2-49CD-A0AC-8FE3C556050AQ40295958-317AC751-7FE3-4E6E-8212-9CAE444DB066Q40410058-D480F250-70EB-4C67-8EDA-1B08779ECCCBQ40468799-574BE6E0-E292-4D70-B4CB-BDA2BFAF114EQ48500160-8DAC2055-064C-498E-9652-6223C1097D24Q52579133-BAFAFD34-1822-489E-9A47-6958CC6AFDFA
P2860
Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
@en
type
label
Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
@en
prefLabel
Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
@en
P2860
P1476
Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity
@en
P2093
Aideen C Allen
P2860
P304
P356
10.1586/14760584.2014.936391
P577
2014-07-12T00:00:00Z